I have had 5 minutes now to review and absorb. Some key...

I have had 5 minutes now to review and absorb. Some key takeaways:

- Amusingly they have put in the initial page that the report is in USD to really emphasise what I was saying before RE: poor due diligence from newer investors.
- $3.3Million in services revenue including IP licencing - curious:


Stage 1 revenue received of $400K? Also they are recognising the $10M over 20 months. Does this mean they are just distributing funds from this cash for the next 20 months? Out of the $3.3M, $1.8M from other service deals outside of Hologic?

- Revenue from product sales much, much higher than i anticipated. Total annual sales for the products in previous years was $300K. In effect doubles annual sales in a quarter. Very promising moving forward. Noting AT1 pumped 30% on a $500,000 purchase order, surprised this didn't intrigue for a larger run. Febridx slower as expected however Viradx is a simpler rat test for covid testing and general flu. Was going to be the primary product for immediate sales.

- They keep noting Aptatek, Food in Dept, Burnett Institute and Micropak - maybe updates in these are due to come soon?

Overall a positive a announcement and hopefully we see some positive trajectory on the SP over the next few weeks. No reason this shouldn't be back around.10c given the current status.